| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Animal models of the cardiovascular effects of exogenous hormones 1 1 Discussion of unlabeled use of products: Estrogens and progestins are not labeled for the prevention of cardiovascular disease.
|
Karas, Richard H
|
|
2002
|
90 |
1S1 |
p. F22-F25
|
artikel
|
| 2 |
Antiatherosclerosis interventions in women 1 1 Discussion of unlabeled use of products: Estrogens and progestins are not labeled for reducing or slowing the progression of atherosclerosis.
|
Hodis, Howard N
|
|
2002
|
90 |
1S1 |
p. F17-F21
|
artikel
|
| 3 |
Clinical cardiovascular studies of hormone replacement therapy 1 1 Discussion of unlabeled use of products: Estrogens, progestins, testosterone, and raloxifene are not labeled for the prevention of coronary artery disease or for any effects they may have on the cardiovascular system.
|
Collins, Peter
|
|
2002
|
90 |
1S1 |
p. F30-F34
|
artikel
|
| 4 |
CME FM
|
|
|
2002
|
90 |
1S1 |
p. F52-F53
|
artikel
|
| 5 |
CME Section
|
|
|
2002
|
90 |
1S1 |
p. F55-F58
|
artikel
|
| 6 |
Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation 1 1 Discussion of unlabeled use of products: Estrogens, progestins, testosterone, and selective estrogen receptor modulators are not labeled for the reduction of risk factors for cardiovascular disease or for any effects they may have on the cardiovascular system.
|
Cushman, Mary
|
|
2002
|
90 |
1S1 |
p. F7-F10
|
artikel
|
| 7 |
Elucidation of the molecular mechanism of action of selective estrogen receptor modulators 1 1 Discussion of unlabeled use of products: Estrogens, progestins, and selective estrogen receptor modulators (SERMs) are not labeled for the prevention of cardiovascular disease. Some estrogens and SERMs are not labeled for the prevention or treatment of osteoporosis in postmenopausal women; readers are encouraged to consult appropriate resources, including full prescribing information, for individual products.
|
McDonnell, Donald P
|
|
2002
|
90 |
1S1 |
p. F35-F43
|
artikel
|
| 8 |
Genomic and nongenomic effects of estrogen in the vasculature 1 1 Discussion of unlabeled use of products: Estrogens are not labeled for any effects they may have on the cardiovascular system or for the treatment of cardiovascular disease.
|
Mendelsohn, Michael E
|
|
2002
|
90 |
1S1 |
p. F3-F6
|
artikel
|
| 9 |
Introduction 1 1 Discussion of unlabeled use of products: Estrogens and progestins are not labeled for the prevention of coronary artery disease.
|
Karas, Richard H
|
|
2002
|
90 |
1S1 |
p. F1-F2
|
artikel
|
| 10 |
Methods for evaluating the effects of new hormone replacement therapy compounds on coronary artery disease 1 1 Discussion of unlabeled use of products: Estrogens and progestins are not labeled for the prevention of cardiovascular disease. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, or “statin” drugs, are not labeled for any effect they may have on coronary artery calcium.
|
Ouyang, Pamela
|
|
2002
|
90 |
1S1 |
p. F44-F50
|
artikel
|
| 11 |
Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence 1 1 Discussion of unlabeled use of products: Estrogens and progestins are not labeled for the prevention of cardiovascular disease.
|
Hu, Frank B
|
|
2002
|
90 |
1S1 |
p. F26-F29
|
artikel
|
| 12 |
Vasomotor and vascular effects of hormone replacement therapy 1 1 Discussion of unlabeled use of products: Estrogens, progestins, and selective estrogen receptor modulators are not labeled for the reduction of risk factors for cardiovascular disease or for any effects they may have on the cardiovascular system.
|
Ganz, Peter
|
|
2002
|
90 |
1S1 |
p. F11-F16
|
artikel
|
Tijdschrift beschrijving